HDAC Inhibition to Prime Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Immunotherapy has made a breakthrough in medical oncology with the approval of several immune checkpoint inhibitors in multiple cancer types. Since only a minority of patients experience a durable response with these agents, combination strategies and novel immunotherapy drugs were d...

Descripción completa

Detalles Bibliográficos
Autores principales: Borcoman, Edith, Kamal, Maud, Marret, Grégoire, Dupain, Celia, Castel-Ajgal, Zahra, Le Tourneau, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750966/
https://www.ncbi.nlm.nih.gov/pubmed/35008230
http://dx.doi.org/10.3390/cancers14010066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750966/
https://www.ncbi.nlm.nih.gov/pubmed/35008230
http://dx.doi.org/10.3390/cancers14010066

Ejemplares similares